Rhythm Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Hi, everyone. Thanks for attending Cannacord Genuity's 43rd Annual Growth Conference. My name is Joohwan Kim, and I'm an associate of (inaudible) and Rare Diseases. We're very excited to have the team from Rhythm Pharmaceuticals here. And it's my great pleasure to introduce David Meeker who is the Chair, CEO, and President. Rhythm is a global biopharmaceutical company leading the space for hyperphagia, a severe obesity caused by rare MC4R pathway diseases.
And so with that, I'll turn it over to the presentation.
So thank you, Joohwan, and welcome, everybody. Apologies for my voice. As you can tell, I'm recovering here in terms of some form of laryngitis. And I think I'm well on the way, but apologies if it's a little harder to understand.
So Rhythm, this is our forward-looking statement. Obviously, I'm not going to read through it. For the slides, this is our corporate deck. It's available on our website, and I won't be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |